Patidegib hydrochloride is a Small Molecule owned by PellePharm, and is involved in 9 clinical trials, of which 8 were completed, and 1 is ongoing.

Patidegib acts by inhibiting SMO (smoothened homolog). SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations. The drug candidate binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival.

The revenue for Patidegib hydrochloride is expected to reach a total of $141m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Patidegib hydrochloride NPV Report.

Patidegib hydrochloride was originated by Infinity Pharmaceuticals and is currently owned by PellePharm. BridgeBio Pharma is the other company associated in development or marketing of Patidegib hydrochloride.

Patidegib hydrochloride Overview

Patidegib is under development for the treatment of Gorlin syndrome. The drug candidate is administered orally and applied topically.  It acts by targeting smoothened homolog. It was under development for the treatment of advanced and/or metastatic solid tumor malignancies and pancreatic cancer. It was also under development for the treatment of myelofibrosis and metastatic or locally advanced (unresectable) chondrosarcoma,  basal cell carcinomas.

BridgeBio Pharma Overview

BridgeBio Pharma (BridgeBio) is a clinical-stage biotechnology company that develops novel medicines for genetic diseases. The company’s pipeline product portfolio includes precision cardiorenal drugs such as acoramidis, encaleret, BBP-711; mendelian disease drugs which include acoramidis, fosdenopterin, patidegib topical gel, low-dose infigratnib, BBP-589, BBP-551, BBP-418, BBP-681, BBP-671, among others; precision oncology drugs which include high-dose infigratinib, BBP-398, BBP-454, BBP-954. BridgeBio also carries out various phases of clinical trials such as pre-clinical, phase I, phase II studies. The company’s academic partners which include Medical University of South Carolina, University of Pittsburgh, Oregon Health, and Science University, among others. Its industry partners which include Helsinn, Alexion, Bristol Myers Squibb, among others. BridgeBio is headquartered in Palo Alto, California, the US.

The company reported revenues of (US Dollars) US$69.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$8.3 million in FY2020. The operating loss of the company was US$576.6 million in FY2021, compared to an operating loss of US$474.5 million in FY2020. The net loss of the company was US$562.5 million in FY2021, compared to a net loss of US$448.7 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 99.5% over the previous quarter.

Quick View – Patidegib hydrochloride

Report Segments
  • Innovator
Drug Name
  • Patidegib hydrochloride
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.